KıSKAÇ, MUHARREMZORLU, MEHMETAKKOYUNLU, MUHAMMED EMİNKILIC, ERDEMCAKIRCA, MUSTAFAKaratoprak, CUMALİYAVUZ, EARDIC, CCAMLI, AHMET ADİLCIKRIKCIOGLU, MKART, L2019-10-052019-10-052014-06-01KıSKAÇ M., ZORLU M., AKKOYUNLU M. E. , KILIC E., Karatoprak C., CAKIRCA M., YAVUZ E., ARDIC C., CAMLI A. A. , CIKRIKCIOGLU M., et al., -Vaspin and lipocalin-2 levels in severe obsructive sleep apnea.-, Journal of thoracic disease, cilt.6, ss.720-5, 2014https://hdl.handle.net/20.500.12645/2302Background: Vaspin and lipocalin-2 are less-known recent members of adipocytokine family. There are ongoing studies investigating the role of vaspin ve lipocalin-2 in metabolic syndrome (MS). Obstructive sleep apnea syndrome (OSAS) is independently associated with an increased prevalence of MS. We aimed to measure the levels of vaspin and lipocalin-2 which are secreted from adipocytes in patients with severe OSAS and examine the relationship between these two adipocytokines and OSAS. Methods: The study consisted of two groups: severe OSAS patients with an apnea-hypopnea index (AHI) of >30/h (OSAS group, 34 subjects) and age-matched healthy volunteers with a AHI <5/h (control group, 25 subjects) Serum levels of vaspin and lipocalin-2 in these two groups were compared. Results: Serum levels of vaspin were significantly lower in OSAS group; patients with severe OSAS compared with control group; healthy volunteers (OSAS group: 0.69±0.5 vs. control group: 1.24±1.13; P=0.034). The difference between the two groups in terms of serum levels of lipocalin-2 has not reached statistical significance (OSAS group: 61.6±18.2 vs. control group: 68.5±20.1; P=0.17). Conclusions: We found that serum vaspin levels were significantly lower in patients with severe OSAS compared with healthy controls. Lipocalin-2 levels were similar. The decrease in serum vaspin levels in severe OSAS patients may be important in diagnosis and follow-up of these patients.eninfo:eu-repo/semantics/openAccessArticle24976995trdizin